Healthcare Industry News: XP13512
News Release - May 1, 2008
XenoPort Appoints Vincent J. Angotti as Chief Commercialization OfficerSANTA CLARA, Calif.--(HSMN NewsFeed)--XenoPort, Inc. (Nasdaq:XNPT ) announced today that Vincent J. Angotti has joined the company as senior vice president and chief commercialization officer. His near-term responsibilities will include strategic marketing, product planning and management of the commercial aspects of alliances with Astellas Pharma, Inc. and GlaxoSmithKline, or GSK, relating to XP13512, XenoPort’s most advanced product candidate. In the event XenoPort exercises the option under its agreement with GSK, Mr. Angotti will assemble and lead the specialty sales force that would co-promote XP13512 in the United States.
Mr. Angotti has over 17 years of sales and marketing experience in both large and specialty pharmaceutical businesses. Most recently, Mr. Angotti served as the senior vice president of sales and marketing at Reliant Pharmaceuticals, Inc. While at Reliant, Mr. Angotti led the expansion of a mass market and specialty sales force in the United States to promote both Lovaza, a treatment for hypertriglyceridemia, and Rythmol SR, a treatment for atrial fibrillation. In addition, he launched co-promotion partnerships with Biovail Corporation and Amylin Pharmaceuticals, Inc. and oversaw marketing, sales, managed markets, operations and forecasting functions. Reliant was acquired by GSK in March 2008.
“We are very pleased to have Vince join our executive management team,” said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort. “With his strong sales and marketing background, Vince will contribute a valuable commercial perspective to important issues that we will consider as we pursue our vision of becoming a fully integrated, CNS-focused pharmaceutical company.”
Prior to joining Reliant in 2001, Mr. Angotti spent ten years at Novartis Pharmaceuticals Corporation, where he most recently acted as executive director of field operations and also held a variety of management positions in sales, training and operations. Mr. Angotti received his Bachelor of Science degree from Cornell University and holds an MBA from Columbia University.
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. Its development and commercialization efforts are currently focused on potential treatments of central nervous system disorders. XenoPort’s most advanced product candidate, XP13512, has successfully completed three pivotal trials in its Phase 3 clinical program for the treatment of moderate-to-severe primary restless legs syndrome and has successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia. XenoPort has also reported positive results from a Phase 2a clinical trial of its second product candidate, XP19986, in patients with gastroesophageal reflux disease. XenoPort has also reported positive results from a Phase 1 clinical trial of its third product candidate, XP21279.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered U.S. trademark.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.